New Report Available: Neurimmune Therapeutics AG - Product Pipeline Review - 2013

Global Market Direct's pharmaceuticals report, "Neurimmune Therapeutics AG - Product Pipeline Review - 2013" provides data on the Neurimmune Therapeutics AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Neurimmune Therapeutics AG's corporate website, SEC filings, investor presentations and featured press releases, both from Neurimmune Therapeutics AG and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

Full Report Details at
- http://www.fastmr.com/prod/647176_neurimmune_therapeutics_ag_product_pipeline.aspx?afid=301

* Neurimmune Therapeutics AG - Brief Neurimmune Therapeutics AG overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Neurimmune Therapeutics AG human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Neurimmune Therapeutics AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Neurimmune Therapeutics AG's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Evaluate Neurimmune Therapeutics AG's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Neurimmune Therapeutics AG in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Neurimmune Therapeutics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Neurimmune Therapeutics AG.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Neurimmune Therapeutics AG and identify potential opportunities in those areas.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Affimed Therapeutics AG - Product Pipeline Review - 2013
- Parkinson's Disease - Pipeline Review, H1 2013
- Inflammatory Bowel Disease - Pipeline Review, H1 2013
- Novartis AG - Product Pipeline Review - 2013
- Post-Operative Pain - Pipeline Review, H1 2013